These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 26492963)
1. Influenza vaccination is safe and effective in patients suffering from fibromyalgia syndrome. Ablin JN; Aloush V; Brill A; Berman M; Barzilai M; Caspi D; Mandelboim M; Levartovsky D; Polachek A; Wolman Y; Paran D; Barkagan M; Elkayam O Reumatismo; 2015 Sep; 67(2):57-61. PubMed ID: 26492963 [TBL] [Abstract][Full Text] [Related]
2. Vaccination against influenza in patients with systemic sclerosis. Litinsky I; Balbir A; Zisman D; Mandelboim M; Mendelson E; Feld J; Braun Y; Anouk M; Kaufman I; Paran D; Caspi D; Elkayam O Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S7-11. PubMed ID: 22409886 [TBL] [Abstract][Full Text] [Related]
3. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy. Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan. Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602 [TBL] [Abstract][Full Text] [Related]
6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948 [TBL] [Abstract][Full Text] [Related]
7. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501 [TBL] [Abstract][Full Text] [Related]
8. Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People. Camilloni B; Basileo M; Menculini G; Tozzi P; Iorio AM Adv Exp Med Biol; 2016; 897():45-53. PubMed ID: 26577530 [TBL] [Abstract][Full Text] [Related]
9. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864 [TBL] [Abstract][Full Text] [Related]
10. [Safety and immunogenicity of seasonal inactivated influenza vaccine (split virion) and cross-reactive antibody responses to the H7N9 avian influenza virus]. Guo W; Xu J; Wu J; Zhao S; He H; Shi W; Yu D; Li J; Gao H; Chen J Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Aug; 35(8):949-52. PubMed ID: 25376689 [TBL] [Abstract][Full Text] [Related]
11. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine. Souza TM; Santini-Oliveira M; Martorelli A; Luz PM; Vasconcellos MT; Giacoia-Gripp CB; Morgado M; Nunes EP; Lemos AS; Ferreira AC; Moreira RI; Veloso VG; Siqueira M; Grinsztejn B; Camacho LA J Med Virol; 2016 Mar; 88(3):426-36. PubMed ID: 26267817 [TBL] [Abstract][Full Text] [Related]
13. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine]. Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010 [TBL] [Abstract][Full Text] [Related]
14. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967 [TBL] [Abstract][Full Text] [Related]
15. Kinetics of the antibody response to seasonal influenza vaccination among the elderly. Kositanont U; Assantachai P; Wasi C; Puthavathana P; Praditsuwan R Viral Immunol; 2012 Dec; 25(6):471-6. PubMed ID: 23061793 [TBL] [Abstract][Full Text] [Related]
16. [Safety and immunogenicity on the formulation of trivalent split influenza vaccine among healthy people aged over 18 years]. Wang P; Zhang XW; Song YF; Yin HB; Liu LJ; Che L; Li H; Liu Y; Chen JT Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Feb; 32(2):120-4. PubMed ID: 21518617 [TBL] [Abstract][Full Text] [Related]
17. Specific antibody response after influenza immunization in systemic lupus erythematosus. Abu-Shakra M; Press J; Varsano N; Levy V; Mendelson E; Sukenik S; Buskila D J Rheumatol; 2002 Dec; 29(12):2555-7. PubMed ID: 12465151 [TBL] [Abstract][Full Text] [Related]
18. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. Nabeshima S; Kashiwagi K; Murata M; Kanamoto Y; Furusyo N; Hayashi J J Med Virol; 2007 Mar; 79(3):320-5. PubMed ID: 17245715 [TBL] [Abstract][Full Text] [Related]
19. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months. Kim YK; Eun BW; Kim NH; Kang EK; Lee BS; Kim DH; Lim JS Scand J Infect Dis; 2013 Jun; 45(6):460-8. PubMed ID: 23294036 [TBL] [Abstract][Full Text] [Related]
20. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. van Assen S; Holvast A; Telgt DS; Benne CA; de Haan A; Westra J; Kallenberg CG; Bijl M Clin Immunol; 2010 Aug; 136(2):228-35. PubMed ID: 20421178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]